Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic

The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.  

Independent thinker concept and new leadership concept or individuality as a group of flying geese with one individual bird going in the opposite direction as a business symbol for innovative thinking and as a different nonconformist maverick.
Engitix Will Retain Full Control Over Its Programs Under The Collaboration. • Source: Alamy

Engitix has inked an R&D deal focused on fibrosis and liver tumors with new investor Dompé Farmaceutici S.p.A. that it hopes will facilitate the UK biotech’s transition from a technology platform to a clinical product company, as it raised $54m in a series A financing.

Under the collaboration, Engitix will retain full control over its assets and programs while Dompé could receive clinical and commercial...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.